NBI-6024 (Neurocrine Biosciences).
Neurocrine is developing NBI-6024 in collaboration with Taisho, as part of Neurocrine's altered peptide ligand (APL) program, as a potential treatment for type I diabetes. By July 2002, Neurocrine had completed four phase I/II trials of NBI-6024 and the compound was in phase IIb studies in Europe and phase Ib studies in the US. By October 2002, a second phase IIb trial was scheduled to begin in the US later in 2002 or in early 2003.
Giannoukakis
Nick
N
Diabetes Institute University of Pittsburgh School of Medicine, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA. ngiann1@pitt.edu